Skip to main content
SpringerLink
Log in
Book cover

Neuro-Psychopharmaka pp 475–484Cite as

Prädiktoren für das Ansprechen auf Psychopharmaka

  • Chapter

Zusammenfassung

Die Frage nach der Voraussagbarkeit des therapeutischen Ansprechens auf Psychopharmaka wurde vor allem bezüglich Antidepressiva und Neuroleptika untersucht. Aus diesem Grund steht die Darstellung der Prädiktorforschung hinsichtlich dieser beiden Substanzgruppen im Mittelpunkt des vorliegenden Beitrages.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   69.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Aagaard J, Vestergaard P, Maarbjerg K (1988) Adherence to lithium prophylaxis. II. Multivariate analysis of clinical, social, and psychosocial predictors of nonadherence. Pharmacopsychiatry 21: 166–170.

    Article  PubMed  CAS  Google Scholar 

  • Abou-Saleh MT, Coppen AJ (1990) Predictors of long-term outcome of mood disorder on prophylactic lithium. Lithium 1: 27–35.

    Google Scholar 

  • Amsterdam JD, Berwish NJ (1989) High dose tranylcypromine therapy for refractory depression. Pharmacopsychiatry 22: 21–25.

    Article  PubMed  CAS  Google Scholar 

  • Angst J (1987) Verlauf der affektiven Psychosen. In: Kisker KP, Lauter H, Meyer JE, Müller C, Strömgren E (Hrsg) Affektive Psychosen. Springer, Berlin Heidelberg New York Tokyo, S 114–133.

    Google Scholar 

  • Angst J, Bech P, Boyer P, Bruinvels J, Engel H, Helmchen H, Hippius H, Lingjaerde O, Racagni G, Saletu B, Sedvall G, Silverstone JT, Stefanis CN, Stoll K, Woggon B (1989) Consensus conference on the methodology of clinical trials of antidepressants, Zurich, march 1988: Report of the Consensus Committee. Pharmacopsychiatry 22: 3–7.

    Article  Google Scholar 

  • Angst J, Stassen HH, Woggon B (1989) Effect of neuroleptics on positive and negative symptoms and the deficit state. Psychopharmacology 99: 41–46.

    Article  Google Scholar 

  • Awad AG (1989) Drug therapy in schizophrenia. Variability of outcome and prediction of response. Can J Psychiatry 34: 711–716.

    PubMed  CAS  Google Scholar 

  • Bartko G, Herczeg I, Bekesy M (1987) Predicting outcome of neuroleptic treatment on the basis of subjective response and early clinical improvement. J Clin Psychiatry 48: 363–365.

    PubMed  CAS  Google Scholar 

  • Bielski RJ, Friedel RO (1976) Prediction of tricyclic antidepressant response. A critical review. Arch Gen Psychiatry 33: 1479–1489.

    Article  PubMed  CAS  Google Scholar 

  • Breyer-Pfaff U (1983) Beziehung zwischen Plasmaspiegel und klinischer Wirkung von Psychopharmaka. In: Huber G (Hrsg) Das ärztliche Gespräch. Symposion, Tropon-Werke Köln.

    Google Scholar 

  • Bridges PK (1983) “… And a small dose of an antidepressant might help”. Br J Psychiatry 142: 626–628.

    Article  PubMed  CAS  Google Scholar 

  • Brotman AW, McCormick S (1990) A role for high-dose antipsychotics. J Clin Psychiatry 51: 164–166.

    PubMed  CAS  Google Scholar 

  • Cfian CH, Janicak PG, Davis JM, Altman E, Andriukaitis S, Hedeker D (1987) Response of psychotic and nonpsychotic depressed patients to tricyclic antidepressants. J Clin Psychiatry 48: 197–200.

    Google Scholar 

  • Coryell W, Endicott J, Keller M (1987) The importance of psychotic features to major depression: course and outcome during a 2-year follow-up. Acta Psychiatr Scand 75: 78–85.

    Article  PubMed  CAS  Google Scholar 

  • Denber HCB (1979) Textbook of clinical psychopharmacology. Thieme, Stuttgart.

    Google Scholar 

  • Dunner DL, Fieve RR (1974) Clinical factors in lithium carbonate prophylaxis failure. Arch Gen Psychiatry 30: 229–233.

    Article  PubMed  CAS  Google Scholar 

  • Fähndrich E (1990) Biologische Prädiktoren für eine erfolgreiche antidepressive medikamentöse Behandlung. In: Möller HJ (Hrsg) Therapieresistenz unter Antidepressiva-Behandlung. Tropon-Symposium V. Springer, Berlin Heidelberg New York Tokyo, S 43–57.

    Chapter  Google Scholar 

  • Fairchild CJ, Rush AJ, Vasavada N, Giles DE, Khatami M (1986) Which depressions respond to placebo. Psychiatry Res 18: 217–226.

    Article  PubMed  CAS  Google Scholar 

  • Faraone SV, Young AS, Brown WA (1989) Neuroleptic non-response and affective symptoms: a 2-year prospective study of schizophrenic outpatients. Psychiatry Res 28: 315–321.

    Article  PubMed  CAS  Google Scholar 

  • Friedel RO (1983) Clinical predictors of treatment response: an update. In: Davis JM, Maas JW (eds) The affective disorders. American Psychiatric Press Inc, Washington, pp 379–384.

    Google Scholar 

  • Goldberg SC (1985) Negative and deficit symptoms in schizophrenia do respond to neuroleptics. Schizophr Bull 11: 453–456.

    Article  PubMed  CAS  Google Scholar 

  • Grof P, Hux M, Grof E, Arato M (1983) Prediction of response to stabilizing lithium treatment. Pharmacopsychiatry 16: 195–200.

    Article  CAS  Google Scholar 

  • Guze BH, Baxter LR, Rego J (1987) Refractory depression treated with high doses of a monoamine oxidase inhibitor. J Clin Psychiatry 48: 31–32.

    PubMed  CAS  Google Scholar 

  • Hollister LE (1973) Clinical use of psychotherapeutic drugs. Charles C Thomas.

    Google Scholar 

  • Hollister LE, Overall JE, Bennett JL, Kimbell I Jr, Shelton J (1967) Specific therapeutic actions of acetophenazine, perphenazine, and benzquinamide in newly admitted schizophrenic patients. Clin Pharmacol Ther 8: 249–255.

    PubMed  CAS  Google Scholar 

  • Joyce PR, Franzep ChB, Paykel ES (1989) Predictors of drug response in depression. Arch Gen Psychiatry 46: 89–99.

    Article  PubMed  CAS  Google Scholar 

  • Keller MB, Klerman GL, Lavori PW, Fawcett JA, Coryell W, Endicott J (1982) Treatment received by depressed patients. JAMA 248: 1848–1855.

    Article  PubMed  CAS  Google Scholar 

  • Kocsis JH, Croughan JL, Katz MM, Butler TP, Secunda S, Bowden CL, Davis JM (1990) Response to treatment with antidepressants of patients with severe or moderate nonpsychotic depression and of patients with psychotic depression. Am J Psychiatry 147: 621–624.

    PubMed  CAS  Google Scholar 

  • Kotin J, Post RM, Goodwin FK (1973) Drug treatment of depressed patients referred for hospitalisation. Am J Psychiatry 130: 1139–1141.

    PubMed  CAS  Google Scholar 

  • Kuhn R (1957) Über die Behandlung depressiver Zustände mit einem Iminodibenzylderivat. Schweiz Med Wochenschr 87: 1135–1140.

    PubMed  CAS  Google Scholar 

  • Kupfer DJ, Frank E, Perel JM (1989) The advantage of early treatment intervention in recurrent depression. Arch Gen Psychiatry 46: 771–775.

    Article  PubMed  CAS  Google Scholar 

  • Kupfer DJ, Shaw DH, Ulrich R, Coble PA, Spiker DG (1982 a) Application of automated REM-analysis in depression. Arch Gen Psychiatry 39: 569–573.

    Article  PubMed  CAS  Google Scholar 

  • Kupfer DJ, Targ E, Stack J (1982 b) Electroencephalographic sleep in unipolar depressive subjects. Support for a biological and familial classification. J Nerv Ment Dis 170: 494–498.

    Article  PubMed  CAS  Google Scholar 

  • Lenz G, Wolf R, Simhandl C, Topitz A, Berner P (1989) Langzeitprognose und Rückfallprophylaxe der schizoaffektiven Psychosen. In: Marneros A (Hrsg) Schizoaffektive Psychosen. Springer, Berlin Heidelberg New York Tokyo, S 55–66.

    Chapter  Google Scholar 

  • Little KY (1988) Amphetamine, but not methylphenidate, predicts antidepressant efficacy. J Clin Psychopharmacol 8: 177–183.

    Article  PubMed  CAS  Google Scholar 

  • Little KY, Gay TL, Vore M (1989) Predictors of response to high dose antipsychotics in chronic schizophrenics. Psychiatry Res 30: 1–9.

    Article  PubMed  CAS  Google Scholar 

  • May PRA, Putten van T, Yale C, Potepan P, Jenden DJ, Dairchild MD, Goldstein ML, Dixon WJ (1976) Predicting individual response to drug treatment in schizophrenia: a test dose model. J Nerv Ment Dis 162: 177–183.

    Article  PubMed  CAS  Google Scholar 

  • Metzger HY, Sommers AA, Luchins W (1986) The effect of neuroleptics and other psychotherapeutic drugs on negative symptoms in schizophrenia. J Clin Psychopharmacol 6: 329–338.

    Article  Google Scholar 

  • Michel K (1986) Suizide und Suizidversuche: Könnte der Arzt mehr tun?. Schweiz Med Wochenschr 116: 770–774.

    PubMed  CAS  Google Scholar 

  • Modestin J (1985) Antidepressive therapy in depressed clinical suicides. Acta Psychiatr Scand 71: 111–116.

    Article  PubMed  CAS  Google Scholar 

  • Möller HJ, Fischer G, von Zerssen D (1987) Prediction of therapeutic response in acute treatment with antidepressants. Eur Arch Psychiatry Neurol Sci 236: 349–357.

    Article  PubMed  Google Scholar 

  • Möller HJ, Kissling W, von Zerssen D (1983) Die prognostische Bedeutung des frühen Ansprechens schizophrener Patienten auf Neuroleptika für den weiteren stationären Behandlungsverlauf. Pharmacopsychiatry 16: 46–49.

    Article  Google Scholar 

  • Möller HJ, Scharl W, von Zerssen D (1985) Vorhersage des Therapieerfolges unter neuroleptischer Akutbehandlung: Ergebnisse einer empirischen Untersuchung an 243 stationär behandelten schizophrenen Patienten. Fortschr Neurol Psychiatr 53: 370–383.

    Article  PubMed  Google Scholar 

  • Nedopil N, Rüther E (1981) Initial improvement as predictor of outcome of neuroleptic treatment. Pharmacopsychiatry 14: 205–207.

    Article  CAS  Google Scholar 

  • Nelson JC, Bowers MB (1978) Delusional unipolar depression: description and drug response. Arch Gen Psychiatry 35: 1321–1328.

    Article  PubMed  CAS  Google Scholar 

  • Overholser JC, Miller IW, Norman WH (1987) The course of depressive symptoms in suicidal vs. nonsuicidal depressed inpatients. J Nerv Ment Dis 175: 450–455.

    Article  PubMed  CAS  Google Scholar 

  • Paykel ES, Hollyman JA, Freeling P, Sedgwick P (1988) Predictors of therapeutic benefit from amitriptyline in mild depression: a general practic placebo-controlled trial. J Affect Disord 14: 83–95.

    Article  PubMed  CAS  Google Scholar 

  • van Putten T, May PRA (1978) Subjective response as a predictor of outcome in pharmacotherapy. Arch Gen Psychiatry 35: 477–480.

    Article  PubMed  Google Scholar 

  • Quitkin FM (1985) The importance of dosage in prescribing antidepressants. Br J Psychiatry 147: 593–597.

    Article  PubMed  CAS  Google Scholar 

  • Quitkin FM, Stewart JW, McGrath PJ, Liebowitz MR, Harrison WM, Trimaco E, Klein DF, Rabkin JG, Markowitz JS, Wagner SG (1988) Phenelzine plus imipramine in the treatment of probable atypical depression: defining syndrome boundaries of selective MAO-responders. Am J Psychiatry 145: 306–311.

    PubMed  CAS  Google Scholar 

  • Remick R (1989) Treatment resistant depression. Psychiatr J Univ Ottawa 14: 394–396.

    CAS  Google Scholar 

  • Rickels K (1981) Benzodiazepines: use and misuse. In: Klein DF, Rabkin J (eds) Anxiety: new research and changing concepts. Raven Press, New York, pp 1–26.

    Google Scholar 

  • Rüther E, Nedopil N, Strauss A (1981) Verlauf schizophrener Psychosen unter neuroleptischer Therapie. Münch Med Wochenschr 123: 803–804.

    Google Scholar 

  • Schatzberg AF, Cole O, Cohen BM, Altesman RI, Sniffin CM (1983) Survey of depressed patients who have failed to respond to treatment. In: Davis JM, Maas IW (eds) The affective disorders. American Psychiatric Press, Washington, DC.

    Google Scholar 

  • Schljckit MA, Feighner JP (1972) Safety of high-dose tricyclic antidepressant therapy. Am J Psychiatry 128: 1456–1459.

    Google Scholar 

  • Schultz SC, Sinicrope P, Kishore P, Friedel RO (1983) Treatment response and ventricular brain enlargement in young schizophrenic patients. Psychopharmacol Bull 19: 510–512.

    Google Scholar 

  • Spiker DG, Weiss JC, Dealy RS, Griffin SJ, Hanin I, Neil JF, Perel JM, Rossi AJ, Soloff PH (1985) The pharmacological treatment of delusional depression. Am J Psychiatry 142: 430–436.

    PubMed  CAS  Google Scholar 

  • Strauss JS, Carpenter WT (1974) The prediction of outcome in schizophrenia. II. Relationship between predictor and outcome variables. Arch Gen Psychiatry 31: 37–42.

    Article  PubMed  CAS  Google Scholar 

  • Strauss JS, Carpenter WT (1977) Prediction of outcome in schizophrenia. III. Five-year outcome and its predictors. Arch Gen Psychiatry 34: 159–163.

    Article  PubMed  CAS  Google Scholar 

  • Tandon R, Goldman RS, Goodson JA, Greden JF (1990) Mutability and relationship between positive and negative symptoms during neuroleptic treatment in schizophrenia. Biol Psychiatry 27: 1323–1326.

    Article  PubMed  CAS  Google Scholar 

  • Wittenborn JR, Kiremitci N (1975) A comparison of antidepressant medications in neurotic and psychotic patients. Arch Gen Psychiatry 32: 1172–1176.

    Article  PubMed  CAS  Google Scholar 

  • Wittenborn JR, Kiremitci N, Weber ESP (1973) The choice of alternative antidepressants. J Nerv Ment Dis 156: 97–108.

    Article  PubMed  CAS  Google Scholar 

  • Woggon B (1979) Klinische Psychopharmakologie. In: Psychiatrische Universitätsklinik Zürich, Forschungsdirektion. Zehnjahresbericht 1969–1979. Zürich, S 67-105.

    Google Scholar 

  • Woggon B (1980) Veränderungen der psychopathologischen Symptomatik während 20tägiger antidepressiver oder neuroleptischer Behandlung. Psychiatria Clin 13: 150–164.

    CAS  Google Scholar 

  • Woggon B (1983) Prognose der Psychopharmakotherapie. Enke, Stuttgart.

    Google Scholar 

  • Woggon B (1987) Psychopharmakotherapie affektiver Psychosen. In: Kisker KP, Lauter H, Meyer JE, Müller C, Strömgren E (Hrsg) Affektive Psychosen. Springer, Berlin Heidelberg New York Tokyo, S 274–325.

    Google Scholar 

  • Woggon B, Bosshart P, Meyer JW, Baumann P (1988) Mögliche Konsequenzen des Debrisoquin-Hydroxylierungsdefektes für die Behandlung mit Psychopharmaka. Zusammenfassung mehrerer Schweizer Untersuchungen. In: Gross G, Huber G (Hrsg) Neuere pharmakopsychiatrische und neurochemische Ergebnisse der Psychosenforschung. Das ärztliche Gespräch 44. Tropon Arzneimittel, Köln, S 79–86.

    Google Scholar 

  • Zemlan FP, Thienhaus OJ, Garver DL (1990) Length of psychiatric hospitalisation and prediction of antipsychotic response. Biol Psychiatry 14: 13–24.

    CAS  Google Scholar 

Download references

Authors
  1. B. Woggon
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Psychiatrische Universitätsklinik, Würzburg, Bundesrepublik Deutschland

    Peter Riederer

  2. Psychiatrische Universitätsklinik, Bonn, Bundesrepublik Deutschland

    Gerd Laux

  3. Psychiatrische Universitätsklinik, Basel, Schweiz

    Walter Pöldinger

Rights and permissions

Reprints and permissions

Copyright information

© 1992 Springer-Verlag Wien

About this chapter

Cite this chapter

Woggon, B. (1992). Prädiktoren für das Ansprechen auf Psychopharmaka. In: Riederer, P., Laux, G., Pöldinger, W. (eds) Neuro-Psychopharmaka. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6674-1_21

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-6674-1_21

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-7091-7377-0

  • Online ISBN: 978-3-7091-6674-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation